Hu, Shanlian
Tang, Zhiliu
Harrison, James P.
Hertel, Nadine
Penrod, John R.
May, Jessica R.
Juarez-Garcia, Ariadna
Holdgate, Orban
Funding for this research was provided by:
bristol-myers squibb
Article History
Accepted: 4 December 2022
First Online: 10 March 2023
Declarations
:
: This analysis was funded by Bristol Myers Squibb. Development of the health economic model, data collection, and data interpretation were funded by Bristol Myers Squibb. Data analysis for this study was partly funded by Bristol Myers Squibb.
: S. Hu is a Health Economics Professor employed by the School of Public Health, Fudan University. Z. Tang was an employee of Sino-American Shanghai Squibb Pharmaceuticals Ltd at the time the work was undertaken. J.P. Harrison, N. Hertel, J.R. Penrod, J.R. May, and A. Juarez-Garcia are employees of Bristol Myers Squibb and report stock ownership in Bristol Myers Squibb. O. Holdgate was an employee of Parexel International at the time the work was undertaken.
: Not applicable
: Not applicable
: Not applicable
: The economic model used in this study is not publicly available to protect commercial-in-confidence information. Details of inputs used to generate the analysis are presented within the Supplemental Materials.
: ZT, JPH, NH, JRP, JRM, and OH contributed to the study conception and design. SH, ZT, JPH, NH, JRP, JRM, AJ-G, and OH performed material preparation, data collection, and analysis. All authors reviewed previous versions of the manuscript and have read and approved the final manuscript.